Back to top
more

Centessa Pharmaceuticals (CNTA)

(Delayed Data from NSDQ)

$9.46 USD

9.46
2,251,501

+0.06 (0.64%)

Updated Apr 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

by Zacks Equity Research

Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.

Ahan Chakraborty headshot

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

by Ahan Chakraborty

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 40.9% in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 35.9% upside potential for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why

by Zacks Equity Research

Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage studies.

Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?

by Zacks Equity Research

Centessa Pharmaceuticals (CNTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

Doximity (DOCS) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Doximity's (DOCS) fiscal first-quarter results are likely to reflect continued strength in its fax, e-signature and telehealth products.

BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q3 sales.

Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q1 sales.

    McKesson (MCK) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    McKesson's (MCK) fiscal first-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

    What's in the Offing for QuidelOrtho (QDEL) in Q2 Earnings?

    by Zacks Equity Research

    QuidelOrtho's (QDEL) second-quarter results are likely to reflect strength across both its COVID and non-COVID businesses.

    AMN Healthcare (AMN) to Post Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    AMN Healthcare's (AMN) second-quarter results are likely to reflect solid demand across all its segments.

    NextGen Healthcare (NXGN) Beats on Q1 Earnings, Cuts FY23 View

    by Zacks Equity Research

    NextGen Healthcare's (NXGN) first-quarter fiscal 2023 results reflect strength in its Recurring revenues.

    Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know

    by Zacks Equity Research

    The mean of analysts' price targets for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) points to a 127.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

    Centessa Pharmaceuticals (CNTA) Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    Centessa Pharmaceuticals (CNTA) has been struggling lately, but the selling pressure may be coming to an end soon.